Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/168740 |
Resumo: | OBJECTIVES: The outcomes of refractory and relapsed acute myeloid leukemia (AML) patients in developing countries are underreported, even though the similar classic regimens are widely used. METHODS: We conducted a retrospective comparison of ‘‘MEC’’ (mitoxantrone, etoposide, and cytarabine) and ‘‘FLAG-IDA’’ (fludarabine, cytarabine, idarubicin, and filgrastim) in adults with first relapse or refractory AML. RESULTS: In total, 60 patients were included, of which 28 patients received MEC and 32 received FLAG-IDA. A complete response (CR) rate of 48.3% was observed. Of the included patients, 16 (27%) died before undergoing bone marrow assessment. No statiscally significant difference in CR rate was found between the two protocols (p=0.447). The median survival in the total cohort was 4 months, with a 3-year overall survival (OS) rate of 9.7%. In a multivariable model including age, fms-like tyrosine kinase 3 (FLT3) status, and stem-cell transplantation (SCT), only the last two indicators remained significant: FLT3-ITD mutation (hazard ratio [HR] =4.6, po0.001) and SCT (HR=0.43, p=0.01). CONCLUSION: In our analysis, there were no significant differences between the chosen regimens. High rates of early toxicity were found, emphasizing the role of supportive care and judicious selection of patients who are eligible for intensive salvage therapy in this setting. The FLT3-ITD mutation and SCT remained significant factors for survival in our study, in line with the results of previous studies. |
id |
USP-19_a346d3384184b8969231c6f59ee9633a |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/168740 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experienceAcute Myeloid LeukemiaSalvage RegimensPrognostic FactorsSurvivalCohort StudyOBJECTIVES: The outcomes of refractory and relapsed acute myeloid leukemia (AML) patients in developing countries are underreported, even though the similar classic regimens are widely used. METHODS: We conducted a retrospective comparison of ‘‘MEC’’ (mitoxantrone, etoposide, and cytarabine) and ‘‘FLAG-IDA’’ (fludarabine, cytarabine, idarubicin, and filgrastim) in adults with first relapse or refractory AML. RESULTS: In total, 60 patients were included, of which 28 patients received MEC and 32 received FLAG-IDA. A complete response (CR) rate of 48.3% was observed. Of the included patients, 16 (27%) died before undergoing bone marrow assessment. No statiscally significant difference in CR rate was found between the two protocols (p=0.447). The median survival in the total cohort was 4 months, with a 3-year overall survival (OS) rate of 9.7%. In a multivariable model including age, fms-like tyrosine kinase 3 (FLT3) status, and stem-cell transplantation (SCT), only the last two indicators remained significant: FLT3-ITD mutation (hazard ratio [HR] =4.6, po0.001) and SCT (HR=0.43, p=0.01). CONCLUSION: In our analysis, there were no significant differences between the chosen regimens. High rates of early toxicity were found, emphasizing the role of supportive care and judicious selection of patients who are eligible for intensive salvage therapy in this setting. The FLT3-ITD mutation and SCT remained significant factors for survival in our study, in line with the results of previous studies.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2020-04-13info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/xmlhttps://www.revistas.usp.br/clinics/article/view/16874010.6061/clinics/2020/e1566Clinics; Vol. 75 (2020); e1566Clinics; v. 75 (2020); e1566Clinics; Vol. 75 (2020); e15661980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/168740/160226https://www.revistas.usp.br/clinics/article/view/168740/160227Copyright (c) 2020 Clinicsinfo:eu-repo/semantics/openAccessSilva, Wellington Fernandes daRosa, Lidiane Inês daSeguro, Fernanda SallesSilveira, Douglas Rafaele AlmeidaBendit, IsraelBuccheri, ValeriaVelloso, Elvira Deolinda Rodrigues PereiraRocha, VandersonRego, Eduardo M.2020-04-13T19:50:02Zoai:revistas.usp.br:article/168740Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2020-04-13T19:50:02Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience |
title |
Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience |
spellingShingle |
Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience Silva, Wellington Fernandes da Acute Myeloid Leukemia Salvage Regimens Prognostic Factors Survival Cohort Study |
title_short |
Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience |
title_full |
Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience |
title_fullStr |
Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience |
title_full_unstemmed |
Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience |
title_sort |
Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience |
author |
Silva, Wellington Fernandes da |
author_facet |
Silva, Wellington Fernandes da Rosa, Lidiane Inês da Seguro, Fernanda Salles Silveira, Douglas Rafaele Almeida Bendit, Israel Buccheri, Valeria Velloso, Elvira Deolinda Rodrigues Pereira Rocha, Vanderson Rego, Eduardo M. |
author_role |
author |
author2 |
Rosa, Lidiane Inês da Seguro, Fernanda Salles Silveira, Douglas Rafaele Almeida Bendit, Israel Buccheri, Valeria Velloso, Elvira Deolinda Rodrigues Pereira Rocha, Vanderson Rego, Eduardo M. |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Silva, Wellington Fernandes da Rosa, Lidiane Inês da Seguro, Fernanda Salles Silveira, Douglas Rafaele Almeida Bendit, Israel Buccheri, Valeria Velloso, Elvira Deolinda Rodrigues Pereira Rocha, Vanderson Rego, Eduardo M. |
dc.subject.por.fl_str_mv |
Acute Myeloid Leukemia Salvage Regimens Prognostic Factors Survival Cohort Study |
topic |
Acute Myeloid Leukemia Salvage Regimens Prognostic Factors Survival Cohort Study |
description |
OBJECTIVES: The outcomes of refractory and relapsed acute myeloid leukemia (AML) patients in developing countries are underreported, even though the similar classic regimens are widely used. METHODS: We conducted a retrospective comparison of ‘‘MEC’’ (mitoxantrone, etoposide, and cytarabine) and ‘‘FLAG-IDA’’ (fludarabine, cytarabine, idarubicin, and filgrastim) in adults with first relapse or refractory AML. RESULTS: In total, 60 patients were included, of which 28 patients received MEC and 32 received FLAG-IDA. A complete response (CR) rate of 48.3% was observed. Of the included patients, 16 (27%) died before undergoing bone marrow assessment. No statiscally significant difference in CR rate was found between the two protocols (p=0.447). The median survival in the total cohort was 4 months, with a 3-year overall survival (OS) rate of 9.7%. In a multivariable model including age, fms-like tyrosine kinase 3 (FLT3) status, and stem-cell transplantation (SCT), only the last two indicators remained significant: FLT3-ITD mutation (hazard ratio [HR] =4.6, po0.001) and SCT (HR=0.43, p=0.01). CONCLUSION: In our analysis, there were no significant differences between the chosen regimens. High rates of early toxicity were found, emphasizing the role of supportive care and judicious selection of patients who are eligible for intensive salvage therapy in this setting. The FLT3-ITD mutation and SCT remained significant factors for survival in our study, in line with the results of previous studies. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-04-13 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/168740 10.6061/clinics/2020/e1566 |
url |
https://www.revistas.usp.br/clinics/article/view/168740 |
identifier_str_mv |
10.6061/clinics/2020/e1566 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/168740/160226 https://www.revistas.usp.br/clinics/article/view/168740/160227 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2020 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/xml |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 75 (2020); e1566 Clinics; v. 75 (2020); e1566 Clinics; Vol. 75 (2020); e1566 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222764738543616 |